Emily Rollins Appointed to Science 37® Board of Directors
October 12 2021 - 7:55AM
Science 37, the Operating System for today’s more agile clinical
trials, announced the appointment of Emily Rollins to the Company’s
Board of Directors. Ms. Rollins will serve as the chairperson for
the Science 37’s Audit Committee.
Ms. Rollins, a retired Deloitte audit and
assurance partner, brings more than 30 years of expertise as she
has guided hundreds of clients—from pre-revenue to $10B+
international public companies—through corporate governance, audit
and reporting processes. She chairs multiple board committees from
various industries. As a deeply trusted advisor to executive teams,
Ms. Rollins is an ideal addition to the Science 37 Board of
Directors.
“We are thrilled to welcome Emily to the Science
37 Board,” said David Coman, Chief Executive Officer of Science 37.
“She is a renowned accounting expert with years of experience
advising companies in various stages of growth from a variety of
industries. She also shares our passion for increasing access to
clinical research for patients and providers—helping make research
more representative and accelerating the development of potentially
life-saving treatments. We are truly fortunate to have the
opportunity to benefit from her perspectives as a board
member.”
“Science 37’s aim to make clinical research more
accessible for more people is a shared passion and being a part of
the Board of Directors at this pivotal moment is an exciting
opportunity for me.” said Emily Rollins, director and Audit
Committee chairperson, Science 37 Board of Directors. “I look
forward to working with the executive team as they look to leverage
their operating system to disrupt the traditional clinical trial
model and make research more efficient to help speed treatments to
market for the people who need them.”
About Science 37: Science 37, Inc.’s
missions it to enable universal access to clinical research—making
it easier for patients and providers to participate from anywhere
and helping to accelerate the development of treatments that impact
patient lives. As a pioneer of decentralized clinical trials, the
Science 37 Clinical Trial Operating System (OS) supports today’s
more agile clinical research designs with its full stack,
end-to-end technology platform and specialized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators and connected devices. Configurable to enable any
study type, the Science 37 OS enables up to 15x faster enrollment,
28% better retention and 3x more diverse patient population with
industry-leading workflow orchestration, evidence generation and
data harmonization. For more information, visit
https://www.science37.com.
MEDIA INQUIRIES:Margie KoomanScience 37Phone:
(984) 377-3737Email: pr@science37.com
INVESTOR RELATIONS:Caroline PaulGilmartin
Groupinvestors@science37.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/efbf2072-662b-45c1-8c03-c2440dc0acf4
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024